Fairfield Market Research Cervical Cancer Treatment Market Size, Share Growth 2023-2030

Cervical Cancer Treatment Market

Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Published Date: Upcoming | Format:

Industry: Pharmaceuticals & Biotechnology


Request TOC Request Customization $4,995.00Prebook

Preliminary analysis of the global cervical cancer treatment market anticipates a moderate growth outlook for the market during the next few years to come. The market is anticipated to expand as more women demand cervical cancer diagnostic tests for early detection.

Market Analysis in Brief

With more than 600,000 new cases and over 342,000 fatalities recorded by the end of 2020, cervical cancer is the fourth most frequent cancer in women worldwide, suggest the World Health Organization Updates from February 2022. Nearly 90% of all new diagnosed cases, and fatalities reportedly occur in the low- and middle-income countries. Due to the rising incidence of cervical cancer in women around the world, the cervical cancer treatment market has experienced significant expansion in the recent past. The general public's growing awareness of cervical cancer's diagnosis, prevention, care, and treatment is expected to significantly contribute toward the expansion of the cervical cancer treatment industry. Moreover, excessive tobacco smoking, weak immune system, unsafe sex life, as well as certain genetic factors further strengthen the case.

Key Report Findings

  • The cervical cancer treatment market size was nearly US$5 Bn in 2021
  • Government programs that promote early cervical cancer diagnosis and treatment also serve a vital role in uplifting market prospects
  • An alarming number of cervical cancer cases happen to be across the developing, and low- and middle-income economies
  • The squamous cell carcinoma represents more than 85% of the identified cervical cancer cases
  • North America’s cervical cancer treatment industry leads with higher promotion of cancer prevention, and better insurance coverage to low-income consumer classes

Growth Drivers

Governments’ Take on Rising Prevalence of Cervical Cancer

The cervical cancer treatment market is expanding as a result of favorable government initiatives aimed at preventing the disease, rising cervical cancer prevalence, growing public awareness of the importance of early detection, and vigorous R&D by major manufacturers of drugs and diagnostic tools for the disease. For instance, the World Health Organization (WHO) launched a global initiative to speed up the elimination of cervical cancer in November 2020 after the World Health Assembly adopted a resolution by 194 countries. The WHO also achieved a historic first by committing to the three crucial steps of vaccination, screening, and treatment to eradicate a malignant disease.

Pap-Smear Tests and Increasing HPV Use

Over 80% of instances of cervical cancer occur in women from low-resource and developing nations, shows research. The difficulty in implementing cytology-based screening programs also dramatically prolongs the time between cervical cancer treatments in countries like India. According to medical professionals, a thorough pre-screening approach is essential for spotting early cervical epithelial alterations. The Pap-Smear test remains the most popular screening procedure for precancerous cervical intraepithelial neoplasia and early-stage invasive cervical cancer. The segment will thus continue to lead the cervical cancer treatment market. The Centers for Disease Control and Prevention (CDCNational)'s Breast and Cervical Cancer Early Detection Program (NBCCEDP) supports low-income women, both uninsured and insured, in receiving timely screenings.

Large-scale Investments in Healthcare System's Infrastructure

Government funding is the main source for upgrading the healthcare infrastructure in developing countries, which is likely to expand access to healthcare. It is anticipated that this will lead to an increase in demand for cervical cancer treatment. Due to the rise in the frequency of chronic cardiac illnesses, notably cervical cancer, in emerging countries, the global cervical cancer treatment market offers attractive potential. Further advancements led to the US Food and Medicine Administration (FDA) approving Merck's drug Keytruda, which intends to offer a second-line alternative for treating persistent, recurring, and metastatic cervical cancer. In a trial by the NIH, TIL therapy showed total remission of cervical cancer that had migrated to other organs.

The COVID-19 Impact

With regard to cervical screening, precancer treatment, and the management of abnormal screening test results, the COVID-19 pandemic caused considerable disruptions in elective health services. Increased cervical cancer cases could result from this, widening the gap between the sexes' health status. Several organizations have been investing effort in developing strategies to lessen the impact of the disruption to cervical treatment and screening. Such initiatives are anticipated to increase demand for treatment during the anticipated period, in turn fostering the cervical cancer treatment market.

Growth Challenges

Lack of Awareness Among Consumers

The development of the cervical cancer treatment market is hampered by a lack of knowledge about the disease as well as other misconceptions. The disease's late diagnosis is a major contributing factor in many women's deaths from cervical cancer. Because of ignorance, many avoid getting sick, which delays getting diagnosed and receiving medication or treatment. Approximately 318 women from the general outpatient clinic were reportedly interviewed as part of a study at the Bowen University Teaching Hospital (BUTH) in Nigeria to gauge their degree of knowledge about cervical cancer. With the main sources of information being health talks and hospital workers, the degree of awareness for cervical cancer was 22.6%, and for screening tests, it was 17.9%.

Overview of Key Segments

Squamous Cell Carcinoma Category to Dominate

In the global cervical cancer treatment market, the squamous cell carcinoma segment outperformed the other segments in terms of revenue share. The most frequent kind, representing more than 85% of all identified cases, is squamous cell carcinoma (SCC). If left untreated, the cervix's High-Grade Squamous Intraepithelial Lesion (HSIL) may develop into SCC. Regular use of Pap tests for screening aids in the early identification and diagnosis of SCC. Women of certain racial groups, such as Hispanic and African-American women, are more likely to develop cervical adenocarcinoma. As seen under a microscope, the histology is used to distinguish between SCC, and adenocarcinoma. The least common type of adenosquamous carcinoma affects tissues that can be both squamous and glandular in the cervical region.

Hospital Pharmacy Key Demand Generator

In the forecast period, the hospital pharmacy segment held the largest cervical cancer treatment market share, and it is anticipated that it will continue to rule the market during the forecast period. Cervical cancer is the leading cause of death in eastern, western, middle, and southern Africa. It is anticipated that these figures would raise demand for cancer therapies during the projection period. The disease of cervical cancer severely burdens middle-aged women all over the world. A middle-class person's primary point of contact for medical care is also the neighborhood hospital. Despite the fact that its identification is a cause for alarm in and of itself, cervical cancer can be defeated with the appropriate therapy from the right specialist at the right time.

Cervical Cancer Treatment Market: Regional Landscape

North America Reigns Supreme

Over the forecast period, it is anticipated that the North American cervical cancer treatment market will account for the largest revenue share. The significant market share is attributable to the high disease prevention knowledge among women in the area and the numerous programs initiated to prevent cervical cancer, which has expanded the reach of insurance coverage for cervical screening tests, particularly for low-income women.

Cervical cancer has been detected as one of the leading causes of death for women in the US. The American Cancer Society estimates that in 2020, roughly 13,800 newly diagnosed instances of invasive cervical cancer, and 4,290 women lost their lives to the disease. With the growing use of screening, the death rate from cervical cancer has decreased over the previous 40 years, often by more than 50%.

Opportunities Flock Asia Pacific

Asia Pacific’s cervical cancer treatment market is anticipated to experience stable revenue growth throughout the forecast period ascribed to rising disease prevalence and consumer awareness, as well as improvements in oncological disease detection and treatment technology. The growing economy in the Asia Pacific region and the resulting focus on preventative healthcare drive the market.

The main drivers of the cervical cancer treatment market growth here, are the pacing adoption of better technologies, an increase in consumer awareness, and an increase in the number of health initiatives by commercial and public organizations. On account of the growing population, the incidence of diseases, and the demand for affordable treatments, it is anticipated to increase steadily over the forecast period. The popularity of biosimilars in developing nations like China, and India may change the region's therapeutic environment.

Global Cervical Cancer Treatment Market: Competitive Landscape

A few of the players in the cervical cancer treatment market include Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited(Mumbai), Sanofi S.A.( France), CLOVIS ONCOLOGY (U.S.), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Vivesto AB (Sweden), Alnylam Pharmaceuticals, Inc (U.S.), Biocon (India), Genentech, Inc (U.S.), and Hetero (India).

Recent Notable Developments

In August 2021, Affinivax Inc. was purchased by UK-based pharmaceutical manufacturer GSK for an unknown sum. GSK Company seeks to diversify its technology-based medicinal research portfolio through this acquisition. AffinivaxInc. is a biopharmaceutical company with headquarters in the US that specializes in delivering drugs, including those for cervical cancer.

Regional Classification of the Global Cervical Cancer Treatment Market is Described Below:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • Spain
  • U.K.
  • Italy
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East and Africa

  • GCC
  • South Africa
  • Rest of Middle East and Africa

*Regions and countries are subject to change based on data availability

Key Elements Included In The Study: Global Cervical Cancer Treatment Market

  • Cervical Cancer Treatment Market by Product/Technology/Grade, Application/End-user, and Region
  • Executive Summary (Opportunity Analysis and Key Trends)
  • Historical Market Size and Estimates, Value, 2018 - 2022
  • Market Value at Regional and Country Level, 2023 - 2030
  • Market Dynamics and Economic Overview
  • Market Size in Value, Growth Rates, and Forecast Figures, 2023 - 2030
  • Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
  • Regional and Product/Grade/Application/End-user Price Trends Analysis
  • Value Chain and Five Force’s Analysis
  • Regional/Sub-region/Country Market Size and Trend Analysis
  • Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

  • The report will be prepared in a PPT format and will be delivered in a PDF format.
  • Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.
  • If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.
  • If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.
  • If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.

Request Table of Contents

Our Research Methodology

Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.

View Methodology
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services